Tags : Lucid Diagnostics

PharmaShots Weekly Snapshot (March 02-06, 2020)

Tuba Khan March 9, 2020

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19 Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, […]readmore

MedTech

Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate

Tuba Khan March 3, 2020

Shots: The Lucid-Penn agreement will evaluate Lucid’s EsoCheck esophageal cell collection device with Collect+Protect technology as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies to manage patients […]readmore

Tags : Lucid Diagnostics

PharmaShots Weekly Snapshot (March 02-06, 2020)

Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Lucid Diagnostics

PharmaShots Weekly Snapshot (March 02-06, 2020)

Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company